Engineering of a bispecific affibody molecule towards HER2 and HER3 by addition of an albumin-binding domain allows for affinity purification and in vivo half-life extension.
about
Fusion to a highly stable consensus albumin binding domain allows for tunable pharmacokineticsThe Use of Gene Ontology Term and KEGG Pathway Enrichment for Analysis of Drug Half-LifeEngineered Multivalency Enhances Affibody-Based HER3 Inhibition and Downregulation in Cancer CellsSimultaneous targeting of two ligand-binding sites on VEGFR2 using biparatopic Affibody molecules results in dramatically improved affinity.A truncated and dimeric format of an Affibody library on bacteria enables FACS-mediated isolation of amyloid-beta aggregation inhibitors with subnanomolar affinity.Improved in vivo anti-tumor effects of IgA-Her2 antibodies through half-life extension and serum exposure enhancement by FcRn targetingEvaluation of an Albumin-Binding Domain Protein Fused to Recombinant Human IL-2 and Its Effects on the Bioactivity and Serum Half-Life of the Cytokine.In vivo evaluation of a novel format of a bivalent HER3-targeting and albumin-binding therapeutic affibody construct.Novel affinity binders for neutralization of vascular endothelial growth factor (VEGF) signaling.Targeting HER3 using mono- and bispecific antibodies or alternative scaffolds.Affibody molecules as engineered protein drugs.In vivo biotinylation and incorporation of a photo-inducible unnatural amino acid to an antibody-binding domain improve site-specific labeling of antibodies.
P2860
Q27701821-A03B2690-518D-4EC0-B256-EFF1D578CCC9Q28552953-19DA257E-ECF5-496E-BEAD-CB377500D5F0Q33691823-23458971-24F3-4BDF-977D-D002BBF4BA53Q35525772-FDF834E1-66F6-4AE9-8FF2-6808549FC4C2Q35694115-E4132E3D-D627-451E-8BB5-AA31BDEAB9A8Q37138332-2A86C2EE-DDC6-456A-A77D-04235A158758Q37611373-9C1D8018-571A-4B33-BB3C-6074C40B1C89Q37660979-CC9CE4DD-7D46-4F31-8E21-FBFECBEE2463Q38820756-000A252F-3A71-4DA4-A18A-031A99BF8A91Q38929801-C4B410E4-D5D1-41F6-9D29-E752FB81744EQ39197528-FC292A13-C6F5-4551-BA3D-1FA38BF16B30Q53027597-35AD7A53-2D25-497F-819C-00C80A5CB5F9
P2860
Engineering of a bispecific affibody molecule towards HER2 and HER3 by addition of an albumin-binding domain allows for affinity purification and in vivo half-life extension.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Engineering of a bispecific af ...... d in vivo half-life extension.
@en
Engineering of a bispecific af ...... d in vivo half-life extension.
@nl
type
label
Engineering of a bispecific af ...... d in vivo half-life extension.
@en
Engineering of a bispecific af ...... d in vivo half-life extension.
@nl
prefLabel
Engineering of a bispecific af ...... d in vivo half-life extension.
@en
Engineering of a bispecific af ...... d in vivo half-life extension.
@nl
P2093
P2860
P356
P1476
Engineering of a bispecific af ...... nd in vivo half-life extension
@en
P2093
Fredrik Y Frejd
Lindvi Gudmundsdotter
Martin Lord
Stefan Ståhl
Tarek Bass
P2860
P304
P356
10.1002/BIOT.201400009
P577
2014-04-23T00:00:00Z